{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T16:55:21Z","timestamp":1793984121059,"version":"4.8.0"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>\n                    Hypertension remains a leading modifiable risk factor for cardiovascular morbidity and mortality, yet blood pressure control rates are suboptimal, partly due to adherence challenges with daily medications. Zilebesiran is an investigational small interfering RNA therapy targeting hepatic angiotensinogen synthesis to achieve prolonged suppression of the renin\u2013angiotensin\u2013aldosterone system. By conjugating the small interfering RNA to\n                    <jats:italic toggle=\"yes\">N<\/jats:italic>\n                    -acetylgalactosamine, zilebesiran is delivered specifically to hepatocytes, leading to &gt;90% reductions in circulating angiotensinogen and consequently lower angiotensin II levels. Early-phase clinical trials have demonstrated dose-dependent, sustained blood pressure reductions with zilebesiran. In a phase 1 trial, single subcutaneous doses \u2265200 mg produced clinically significant declines in 24-hour ambulatory systolic\/diastolic blood pressure (mean reductions &gt;10\/5 mm Hg) within 8 weeks, with effects persisting for up to 6 months. A subsequent phase 2 trial (EKG Anywhere Anytime-1) confirmed that quarterly or biannual zilebesiran dosing can achieve 24-hour systolic blood pressure reductions on the order of 10\u201315 mm Hg versus placebo at 3 months (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt; 0.001). Zilebesiran has been well tolerated to date, with mild injection-site reactions and occasional transient mild hyperkalemia as the primary adverse effects. No serious hypotension or renal impairment attributable to renin\u2013angiotensin\u2013aldosterone system suppression has been observed in short-term studies. Therapeutic applications under investigation include use as monotherapy in patients with essential hypertension and as an adjunct for patients with resistant hypertension or high cardiovascular risk. This manuscript provides a comprehensive overview of zilebesiran\u2019s mechanism of action, pharmacokinetics\/pharmacodynamics, clinical trial evidence, potential role in hypertension management and related conditions, as well as its safety and tolerability profile, based on current peer-reviewed data.\n                  <\/jats:p>","DOI":"10.1097\/crd.0000000000000962","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T09:00:37Z","timestamp":1748854837000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Zilebesiran: A Novel RNA Interference Therapeutic for Hypertension"],"prefix":"10.1097","author":[{"given":"Darshilkumar","family":"Maheta","sequence":"first","affiliation":[{"name":"Department of Public Health, New York Medical College, Valhalla, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freya","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Medical College\/Landmark Medical Center, Woonsocket, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valbona","family":"Biba","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Medical College\/Landmark Medical Center, Woonsocket, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ngaba Neguemadji","family":"Ngardig","sequence":"additional","affiliation":[{"name":"Department of Medicine, BronxCare Health System-Icahn Mount Sinai School of Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddharth Pravin","family":"Agrawal","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Medical College\/Landmark Medical Center, Woonsocket, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaysingh","family":"Rajput","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, Montgomery Baptist Family Medicine Residency program, University of Alabama School of Medicine in Birmingham, Montgomery, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avinaash Raja","family":"Sager","sequence":"additional","affiliation":[{"name":"Department of Medicine, Boston Medical Center, Boston University school of Medicine, Brighton, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Medical College, Valhalla, NY; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilbert S.","family":"Aronow","sequence":"additional","affiliation":[{"name":"Departments of Medicine and Cardiology, New York Medical College and Westchester Medical Center, Valhalla, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,6,2]]},"reference":[{"key":"R1-20250602","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2208391","article-title":"Zilebesiran, an RNA interference therapeutic agent for hypertension.","volume":"389","author":"Desai","year":"2023","journal-title":"N Engl J Med"},{"key":"R2-20250602","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/MS9.0000000000002696","article-title":"Advancing hypertension management: the role of zilebesiran as an siRNA therapeutic agent.","volume":"87","author":"Siddiqui","year":"2025","journal-title":"Ann Med Surg (Lond)"},{"key":"R3-20250602","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/CRD.0000000000000645","article-title":"Zilebesiran: a promising antihypertensive therapy inhibiting angiotensinogen synthesis.","volume":"33","author":"Khan","year":"2025","journal-title":"Cardiol Rev"},{"key":"R4-20250602","first-page":"210","article-title":"Zilebesiran: a potential life-altering remedy for hypertensive patients.","volume":"150","author":"Faheem","year":"2025","journal-title":"Cardiology"},{"key":"R5-20250602","first-page":"3651","article-title":"Zilebesiran: The first siRNA drug therapy for hypertension.","author":"Sultana","year":"2024","journal-title":"(IJISRT)"},{"key":"R6-20250602","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1161\/HYPERTENSIONAHA.119.12703","article-title":"Strong and sustained antihypertensive effect of small interfering RNA targeting liver angiotensinogen.","volume":"73","author":"Uijl","year":"2019","journal-title":"Hypertension"},{"key":"R7-20250602","doi-asserted-by":"crossref","first-page":"11649","DOI":"10.3390\/ijms241411649","article-title":"Bradykinin metabolism and drug-induced angioedema.","volume":"24","author":"Smolinska","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R8-20250602","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/jcph.2337","article-title":"Pharmacokinetics and Pharmacodynamics of GALNAC\u2010Conjugated siRNAs.","volume":"64","author":"An","year":"2023","journal-title":"J Clin Pharmacol"},{"key":"R10-20250602","author":"Taubel"},{"key":"R11-20250602","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1001\/jama.2024.0728","article-title":"RNA interference with zilebesiran for mild to moderate hypertension: the KARDIA-1 randomized clinical trial.","volume":"331","author":"Bakris","year":"2024","journal-title":"JAMA"},{"key":"R14-20250602","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1093\/cvr\/cvae140","article-title":"Zilebesiran, a ribonucleic acid interference agent targeting angiotensinogen, proves a promising approach in hypertension.","volume":"120","author":"Webb","year":"2024","journal-title":"Cardiovasc Res"},{"key":"R15-20250602","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1161\/HYPERTENSIONAHA.122.19430","article-title":"Novel pharmacological approaches in the treatment of hypertension: a focus on RNA-Based therapeutics.","volume":"80","author":"Addison","year":"2023","journal-title":"Hypertension"},{"key":"R16-20250602","first-page":"191","article-title":"Impact of IONIS-AGT-Lrx on RAAS pathway inhibition and blood pressure control: promising results from phase 2 trials in hypertension and heart failure.","volume":"8","author":"Michaelsen","year":"2023","journal-title":"J Diabetes Complicat Med"},{"key":"R17-20250602","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.kint.2017.08.038","article-title":"Revisiting RAAS blockade in CKD with newer potassium-binding drugs.","volume":"93","author":"Georgianos","year":"2018","journal-title":"Kidney Int"},{"key":"R18-20250602","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1053\/j.ajkd.2023.09.009","article-title":"Entering a new era of antihypertensive therapy.","volume":"83","author":"Cohen","year":"2023","journal-title":"Am J Kidney Dis"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000962","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T09:00:40Z","timestamp":1748854840000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,2]]},"references-count":15,"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000962","relation":{},"ISSN":["1538-4683"],"issn-type":[{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,2]]}}}